- Conditions
- Cardiac Amyloidosis
- Interventions
- AI ECG Amyloid algorithm
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 121
matching trials from the live ClinicalTrials.gov search.
- Conditions
- ATM Gene Mutation, ATR Gene Mutation, BARD1 Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, CHEK1 Gene Mutation, CHEK2 Gene Mutation, FANCA Gene Mutation, FANCC Gene Mutation, FANCD2 Gene Mutation, FANCF Gene Mutation, FANCM Gene Mutation, NBN Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, RAD51B Gene Mutation, RAD54L Gene Mutation, Recurrent Squamous Cell Lung Carcinoma, RPA1 Gene Mutation, Stage IV Squamous Cell Lung Carcinoma AJCC v7
- Interventions
- Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
- Other · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1151
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 713 more
- Conditions
- Colorectal Neoplasms, Digestive System Diseases, Colonic Diseases, Colorectal Cancer
- Interventions
- Not listed
- Lead sponsor
- Exact Sciences Corporation
- Industry
- Eligibility
- 50 Years to 84 Years
- Enrollment
- 12,776 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 182
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 130 more
- Conditions
- Acute Kidney Injury
- Interventions
- Acute Kidney Injury in Care Transitions (ACT), Usual Care
- Behavioral
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 3
- States / cities
- Mankato, Minnesota • Rochester, Minnesota • Eau Claire, Wisconsin
- Conditions
- Node Positive HER2 Negative Breast Cancer
- Interventions
- Placebo, Aspirin
- Other · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 3,021 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1426
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 902 more
- Conditions
- Hospitalization
- Interventions
- Early Screen for Discharge Planning
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Eau Claire, Wisconsin
- Conditions
- Communication Research
- Interventions
- Med Wise Rx
- Behavioral
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Eau Claire, Wisconsin • Greendale, Wisconsin • Kenosha, Wisconsin + 1 more
- Conditions
- Smoldering Plasma Cell Myeloma
- Interventions
- Daratumumab, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Questionnaire Administration
- Biological · Drug · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 742
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 490 more
- Conditions
- Plasma Cell Myeloma
- Interventions
- Bortezomib, Carfilzomib, Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide, Quality-of-Life Assessment
- Drug · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1,087 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2034
- U.S. locations
- 909
- States / cities
- Anchorage, Alaska • Scottsdale, Arizona • Hot Springs, Arkansas + 551 more
- Conditions
- Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
- Interventions
- Docetaxel, Durvalumab, Erlotinib Hydrochloride, FGFR Inhibitor AZD4547, Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Palbociclib, Pharmacological Study, Rilotumumab, Talazoparib, Taselisib, Tremelimumab
- Drug · Biological · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1,864 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 998
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 639 more
- Conditions
- Breast Cancer
- Interventions
- Elacestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen
- Drug
- Lead sponsor
- Stemline Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 176
- States / cities
- Daphne, Alabama • Chandler, Arizona • Gilbert, Arizona + 139 more
- Conditions
- Head and Neck Squamous Cell Carcinoma, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
- Interventions
- Gabapentin, Placebo, Chemotheraphy, Radiation Therapy, Analgesic Agent, Biospecimen Collection, Survey Administration
- Drug · Radiation · Procedure + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 212
- States / cities
- Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 171 more
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
- Interventions
- Anastrozole, Letrozole, Exemestane, Tamoxifen, Mammogram, Magnetic Resonance Imaging, Dual X-ray Absorptiometry, Biospecimen Collection, Questionnaire Administration
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,556 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 728
- States / cities
- Anchorage, Alaska • Gilbert, Arizona • Goodyear, Arizona + 559 more
- Conditions
- Chronic Pain, Opioid Use
- Interventions
- Slow Tapering of Chronic Opioid Therapy
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 2
- States / cities
- Eau Claire, Wisconsin
- Conditions
- Depressive Disorder, Anxiety, Adolescent
- Interventions
- Breathing Intervention
- Behavioral
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Albert Lea, Minnesota • Eau Claire, Wisconsin
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Pembrolizumab
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 533
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 340 more
- Conditions
- COVID-19 Severe Pneumonia, Acute Lung Injury, Acute Respiratory Distress Syndrome, Pneumonia, Viral
- Interventions
- Ravulizumab, BSC
- Biological · Other
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 24
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Orange, California + 17 more
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Malignant Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma
- Interventions
- Behavioral Dietary Intervention, Compliance Monitoring, Counseling, Educational Intervention, Exercise Intervention, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
- Behavioral · Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,070 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 687
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 452 more
- Conditions
- Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Loss of Heterozygosity, Lung Non-Small Cell Squamous Carcinoma, Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Rucaparib
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 950
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 630 more
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2+ Breast Cancer
- Interventions
- Trastuzumab (Herceptin), Pertuzumab, Echocardiography, Multigated Acquisition Scan, Mammography, Ultrasound, Magnetic Resonance Imaging, Biospecimen Collection, Questionnaire Administration
- Biological · Procedure · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,524 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2037
- U.S. locations
- 698
- States / cities
- Phoenix, Arizona • Fort Smith, Arkansas • Jonesboro, Arkansas + 537 more
- Conditions
- Lumbar Spinal Stenosis
- Interventions
- MILD, Interspinous Process Decompression
- Device
- Lead sponsor
- Stryker Instruments
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 2383
- States / cities
- Athens, Alabama • Bay Minette, Alabama • Birmingham, Alabama + 1285 more
- Conditions
- Non-Pharmacological Pain Management
- Interventions
- Non-pharmacological Options in post-operative Hospital and Rehabilitative Management (NOHARM)
- Behavioral
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Mankato, Minnesota + 3 more
- Conditions
- Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
- Interventions
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
- Biological · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1201
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 735 more
- Conditions
- Colorectal Neoplasms
- Interventions
- Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2032
- U.S. locations
- 989
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 616 more